Skip to content

Home / Knowledge hub / Beyond the contract: Driving transformational partnerships with manufacturing… and more

Beyond the contract: Driving transformational partnerships with manufacturing… and more

November 20, 2025

Achieving scientific breakthroughs is just one hurdle in today’s drug development and manufacturing process aimed at improving patient outcomes. Bringing a new therapy to market requires meticulous execution and clear communication at every step. Unfortunately, even the most groundbreaking scientific advancements can be delayed or even entirely abandoned due to poor performance from partners. This is why the quality of the relationship with a contract development and manufacturing organization (CDMO) really matters. A strong CDMO partnership can accelerate processes and ultimately deliver better outcomes for patients.

The team at Kindeva believes in going beyond the traditional transactional contract. We are committed to transforming the CDMO-client relationship into a true partnership built on consistency, transparency and trust, all designed for long-term success.

In this blog post, we explore how Kindeva’s customer-first mindset, subject matter expert (SME)-led model and capabilities work together to deliver measurable outcomes, mitigate risks and help our partners bring life-changing therapies to patients who need them.


Why customer experience matters


In recent years, the role of CDMOs has profoundly changed. What once were primarily transactional service providers focused on execution have evolved into indispensable strategic partners. Today’s pharmaceutical and biotech clients demand more than just technical capability: they seek foresight, seamless integration and a partner as invested in their program’s success as they are. This significant shift is being shaped by market forces and increasingly complex program demands:

  • Increasing therapeutic complexity
    Modern therapies are becoming increasingly complex and specialized. This requires a deeper level of technical alignment and more robust risk management strategies throughout every stage of the development process.
  • Greater market volatility
    In a dynamic market, launch success is no longer guaranteed by technical expertise alone. It also hinges on adaptability, strong integration across various functions and the ability of a partner to anticipate and effectively manage change.
  • Rising customer expectations
    Clients are now actively seeking CDMOs that can offer strategic input, ensure clear and consistent communication, and provide the flexibility to scale operations in alignment with their evolving needs.

In this environment, customer experience has become not just a preference, but an essential element for building truly impactful partnerships that deliver.

At the core of Kindeva’s distinctive approach is an unwavering commitment to consistency, flexibility and diligent follow-through. Our SME-led model is designed to build deep alignment between our internal teams and our clients, promoting trust and significantly reducing the potential for missteps or unnecessary handoffs. We believe in embedding our teams early in the process, listening actively to understand each client’s unique needs and adapting fluidly to their specific program goals and culture. This collaborative approach helps create a solid foundation for a lasting, productive partnership from the outset, which in turn shapes every subsequent action: how we plan, how we communicate and how we drive each program forward with a shared focus and accountability.

 

A customer-centric approach in action


At Kindeva, our approach is to become an extension of each client’s team. This means aligning with their unique culture, specific program goals and inherent risk profile. Our approach is proactive and collaborative, beginning with the early integration of multidisciplinary teams into the development process. This early integration is crucial, as it enables us to establish strong alignment from the outset and anticipate potential challenges before they materialize.

Our experts operate as one integrated team across development, device, regulatory and manufacturing. This creates a powerful dynamic that consistently reduces risk throughout the entire development process, streamlining timelines. Kindeva is uniquely positioned to help partners with programs from initial concept through to commercialization.

This customer-centric philosophy is supported by a set of core values that guide every interaction and decision. We call these our PRECISE values:

  • Personal responsibility
  • Respect
  • Energy
  • Communication
  • Innovation
  • Service
  • Excellence

These values are the driving principles that define how Kindeva engages with clients, manages projects and ensures shared success.


Delivering value beyond manufacturing


As we have explored, the journey of drug development and manufacturing today demands a shift from traditional transactional relationships to truly transformative partnerships. Kindeva’s commitment to going beyond the contract is evident in every aspect of our operations, from our proactive customer-centric philosophy to our cutting-edge capabilities.

We have seen how our PRECISE values and SME-led model promote alignment, consistent communication and a shared sense of accountability, significantly reducing friction and accelerating progress.

Ultimately, Kindeva’s approach is about more than just manufacturing — it’s about building enduring partnerships that deliver exceptional value. By unifying core functions, embracing innovation and consistently putting the client and patient first, we empower our partners to navigate complexity with confidence. This strategy enables faster time to market, enhanced compliance and, most importantly, better outcomes for patients worldwide. Together, we are building the better tomorrows that the healthcare landscape urgently needs.


Ready to learn how a strategic CDMO partnership can revolutionize your drug development and manufacturing initiatives?

Download our recent eBook on the Kindeva customer experience to explore our comprehensive approach and discover how we can help you manufacture more tomorrows.

Download here.

Related resources

Explore our other resources to discover valuable insights on the latest trends in drug delivery.

The bridge to uncompromising fill finish precision

Sterile fill finish is a sequence of tightly connected control points, where performance at each stage directly influences quality, timelines and patient safety. Bridgeton is designed to deliver control at every step of the fill finish journey. Our 155,000 sq. ft. aseptic facility combines advanced automation, gloveless isolator technology and structured process design to reduce […]

Learn More

The bridge to the future of sterile injectables

Access a sterile fill finish solution designed to help your product progress from formulation through commercial scale with greater confidence and control. Having invested over $200M in our purpose-built, Annex 1-aligned facility in Bridgeton, MO, we bring together the infrastructure, expertise and control needed to accelerate your path to market. From early development through to […]

Learn More

Your bridge to commercial sterile manufacturing

Sterile fill finish has changed. Annex 1 compliance and data transparency are no longer future considerations; they are the baseline. At the same time, programs are expected to move faster, scale seamlessly and maintain absolute control from the first clinical batch through commercial supply. Siloed models cannot keep up with the pace and control required […]

Learn More

Manufacturing more sustainable tomorrows for pulmonary care

The shift to more sustainable inhalers is gaining pace. As pressure grows to reduce their environmental impact, low-Global Warming Potential (GWP) propellants are becoming an important part of the future of metered dose inhaler (MDI) development. In this infographic, we explore the trends shaping that transition, and share how Kindeva is helping partners prepare for […]

Learn More

Parenteral precision: Annex 1-ready sterile fill finish by design

Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. This first blog focuses on Annex 1-ready sterile fill finish. As the European Union […]

Learn More

Beyond the bench: Aerosol analysis and the physics of MDI performance

Modern drug delivery is built on an architecture of precision and predictability to ensure patient safety. Behind every successful inhalation therapy lies a methodical application of analytical science that characterizes the behavior of complex aerosol systems. In this Beyond the bench blog, we examine how this analytical backbone supports the development of pressurized metered-dose inhalers […]

Learn More

Powering every breath you give: Our world-class Loughborough site

Pulmonary drug delivery is undergoing a period of rapid change. Developers must bring increasingly complex therapies to market while preparing inhalers for the transition to low-Global Warming Potential (GWP) propellant technologies.  Success depends on having expertise across formulation, device integration and scalable manufacturing capabilities.  Kindeva’s Loughborough, UK facility stands ready for this evolution. Our global […]

Learn More

Parenteral capabilities overview

Next-generation biologics and combination products require precision and close coordination between drug delivery technologies and manufacturing execution. Kindeva advances parenteral programs across development and commercial supply by bringing together device expertise, aseptic manufacturing and scalable operations. Why choose Kindeva for your parental program Large-scale sterile fill finish The Bridgeton site supports vial, cartridge and prefilled […]

Learn More

Navigating the green revolution: Why next-generation propellants are critical for pMDIs

The imperative to address climate change is reshaping industries worldwide, and pharmaceutical manufacturers are no exception. In respiratory medicine, the spotlight has fallen on pressurized metered-dose inhalers (pMDIs). While crucial for millions of patients, pMDIs harness propellants with a global warming potential (GWP) many times higher than CO2. This significant environmental footprint is a critical […]

Learn More

Let’s transform tomorrow together

Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.